Search the Newsreel

5 Must-Read Analyst Questions From Health Catalyst’s Q2 Earnings Call

Health Catalyst (HCAT) reported a notable decline in Q2 sales, attributed to client migrations and divestiture of its Vitalware business. While revenue slightly beat analyst estimates, the company lowered its full-year guidance and faces ongoing structural challenges in health systems. Analysts pressed management on …

Health Catalyst sells VitalWare for $147Mn

Health Catalyst sold its VitalWare subsidiary to Med-Metrix for $147 million in cash, completed on July 31, 2026. This divestiture allowed Health Catalyst to eliminate its credit facility and focus entirely on healthcare intelligence, analytics, and AI. VitalWare, which provides mid-revenue cycle management solutions, …

Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $2.95. The company recently reported better-than-expected quarterly EPS of $0.04 and revenue of $70.49 million, though it remains unprofitable with a negative net margin. …

Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup

Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.50 to $2.00, while maintaining a "neutral" rating, indicating a potential 12% upside from its previous close. Despite beating quarterly EPS and revenue estimates, the company continues to report substantial losses, and analysts …

HCAT Maintained by Citigroup -- Price Target Lowered to $2.00

Citigroup has maintained a neutral rating for Health Catalyst (HCAT) but lowered its price target from $2.50 to $2.00. Despite the stock being potentially undervalued by 58.8% according to GuruFocus's GF Value, concerns remain about the company's profitability and valuation. Investors are advised to …

Health Catalyst Inc (HCAT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Health Catalyst (NASDAQ:HCAT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Health Catalyst (NASDAQ:HCAT) reported stronger-than-expected Q2 earnings, with an adjusted EPS of $0.04 and revenue of $70.49 million, surpassing analyst estimates. Despite the beat, the company cut its Q3 and full-year 2026 revenue guidance due to anticipated migration-related churn and costs, leading to a …

Health Catalyst (HCAT) Stock Price Sinks On Margin Reset Fears

Health Catalyst (HCAT) saw its stock price drop by 25% following its Q2 2026 report, despite headline numbers not indicating a collapse. The decline is attributed to investor concerns over a changing margin profile due to the sale of the Vitalware unit, the transition …

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Health Catalyst (HCAT) shares fell 23.1% after the company issued a weak third-quarter revenue forecast and lowered its full-year outlook, despite exceeding second-quarter revenue expectations. The reduced guidance overshadowed the company's Q2 performance and indicates significant challenges ahead. This significant drop follows a recent …

Health Catalyst Shares Tumble Overnight: What Investors Need to Know

Health Catalyst (HCAT) shares plummeted 24.68% in overnight trading after the company issued lower-than-expected third-quarter revenue guidance, despite exceeding its second-quarter revenue guidance. The healthcare intelligence company reported a 13% year-over-year revenue decline in Q2 but saw adjusted EBITDA increase. Investors reacted negatively to …

Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics

Health Catalyst (HCAT) reported Q2 2026 revenue of $70.49 million, exceeding the Zacks Consensus Estimate by 2.33%, despite a 12.7% year-over-year decline. The company's EPS of $0.04 surpassed the consensus estimate of $0.02 by 100%. Key metrics like professional services revenue and adjusted gross …

HCAT Q2 Deep Dive: Vitalware Divestiture Reshapes Strategy Amid Revenue Decline

Health Catalyst (Nasdaq: HCAT) sells Vitalware, ends credit facility debt

Health Catalyst (HCAT) has completed the sale of its Vitalware business to Med-Metrix for $147 million, using the proceeds to fully repay its credit facility debt of $159.9 million. This move is expected to eliminate approximately $19 million in annual interest expenses and will …

Health Catalyst (NASDAQ: HCAT) books $151.6M loss and $147M Vitalware sale

Health Catalyst, Inc. (NASDAQ: HCAT) reported a net loss of $151.6 million for the first half of 2026, primarily due to a $122.5 million goodwill impairment charge. The company also announced the sale of its Vitalware business to Med-Metrix for $147 million, with the …

Health Catalyst, Inc. 2026: Revenue $70.49M, EPS ($0.55) — 10-Q Summary

Health Catalyst, Inc. (HCAT) reported Q3 2026 revenue of $70.49 million, a decline from $80.72 million in the prior year, and a net loss of ($0.55) per diluted share. The company attributes the revenue drop to customer churn from DOS-to-Ignite migrations and the exit …

Press Release: Health Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Company

Health Catalyst has announced the completion of the sale of its Vitalware business to RLDatix. This strategic move allows Health Catalyst to sharpen its focus on its core healthcare intelligence and analytics offerings, streamlining its operations and strengthening its balance sheet. The company anticipates …

Earnings call transcript: Health Catalyst posts Q2 2026 revenue beat, shares sink

Health Catalyst (HCAT) reported Q2 2026 revenue above Wall Street expectations, reaching $70.5 million, and adjusted EBITDA at the high end of guidance. However, the company's shares sank by over 27% in after-hours trading due to a weaker full-year outlook, which was primarily impacted …

Health Catalyst (NASDAQ:HCAT) Exceeds Q2 CY2026 Expectations But Stock Drops 25.5%

Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 results that surpassed revenue expectations but showed a 12.7% year-on-year sales decline. Despite exceeding revenue and adjusted EBITDA estimates, the company's stock dropped 25.5% due to lower-than-expected revenue guidance for the next quarter and the full year, along …

M&A: Health Catalyst Closes $147M Sale of Vitalware to Med-Metrix

Health Catalyst, a healthcare intelligence company, has completed the sale of its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million. This divestiture allows Health Catalyst to repay its credit facility, eliminating approximately $19 million in annual interest expense, and focus its capital and …

HEALTH CATALYST ($HCAT) Releases Q2 2026 Earnings

HEALTH CATALYST ($HCAT) announced its Q2 2026 earnings, reporting $0.04 per share, beating estimates by $0.01, and revenue of $70.49 million, surpassing estimates. Despite strong earnings, the stock price decreased by 27.83% since market close. The article also details recent hedge fund activity in …

Health Catalyst Reports Second Quarter 2026 Results

Health Catalyst (Nasdaq: HCAT) reported its financial results for the second quarter ended June 30, 2026, exceeding revenue guidance and adjusting EBITDA. The company's CEO, Ben Albert, highlighted the Vitalware divestiture and debt repayment as significant balance sheet improvements. Health Catalyst also provided its …

Health Catalyst Tries To Reset With A Vitalware Sale

Health Catalyst (HCAT) plans to sell its Vitalware product line for $147 million to reduce debt and improve margins, aiming to refocus on its higher-growth Ignite platform and AI-enabled solutions. While the company faces significant operating losses and negative returns on invested capital, the …

Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For

Health Catalyst (HCAT) is set to report its Q2 earnings, with analysts expecting a 14.6% year-on-year revenue decline. The company beat revenue expectations last quarter but issued slower guidance. While the data and analytics software segment has shown positive investor sentiment, Health Catalyst's stock …

Health Catalyst, Inc. expected to post earnings of 3 cents a share - Earnings Preview

Health Catalyst, Inc. (HCAT) is projected to report earnings of 3 cents per share. This earnings preview, sourced from Refinitiv via Reuters, indicates the anticipated financial performance for the company. The full article provides further details on these expectations.

nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks Shares Are Soaring, What You Need To Know

Shares of nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks surged following easing geopolitical tensions and a new wave of AI-driven M&A activity. A diplomatic resolution regarding the Strait of Hormuz led to a drop in Treasury yields, benefiting growth-oriented tech equities. The …

Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026

Health Catalyst, Inc. (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call to discuss these results at 5:00 pm ET on the same day. Details for accessing …

Health Catalyst Q2 Results: Operating results due August 6, 2026 after market close

Health Catalyst, Inc. announced it will release its second-quarter 2026 operating results on Thursday, August 6, 2026, after market close. A conference call is scheduled for 5:00 pm ET the same day, with details provided for U.S. and international dial-in, as well as a …

Health Catalyst's Aug. 6 call offers a live online webcast

Health Catalyst (Nasdaq: HCAT) will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call on the same day at 5:00 p.m. ET to discuss the results, which will be accessible …

Health Catalyst Inc (HCAT) Institutional Confidence

Health Catalyst Inc (HCAT) has an institutional shareholding score of 7.00, placing it 139th out of 486 in the Software & IT Services industry. The institutional shareholding proportion increased by 3.83% quarter-over-quarter to 84.30%. James Simons is the largest institutional shareholder, holding 0.29% of …

Health Catalyst Announces Date for Second Quarter 2026 Earnings Release and Conference Call

Health Catalyst, Inc. Revenue Breakdown – LSX:A2PH3J

Health Catalyst, Inc. generated a total revenue of €264.91 million last year, with its Technology segment contributing the most at €177.33 million. The United States was the largest regional contributor, accounting for €255.11 million of the company's revenue. These figures provide insight into the …

HCAT|Health Catalyst Inc|Price:2.025|Chg%:+0.015

Health Catalyst Inc. (HCAT) is a provider of data and analytics technology and services to healthcare organizations, operating through Technology and Professional Services segments. The company's stock closed at $2.070, up 2.99%, with a market cap of $149.10 million. In Q1 2026, its recurring …

Health Catalyst Inc (HCAT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Health Catalyst Inc (HCAT), noting its current valuation score of 8.01, which ranks 296 out of 485 in the Software & IT Services industry. It highlights the company's P/E ratio of -0.56, indicating it is -43.75% below …